Literature DB >> 16317866

Banning all drug promotion is the best option pending major reforms.

Peter R Mansfield1.   

Abstract

Drug promotion should be evaluated according to its impact on health, access to information, informed consent, and wealth. Drug promotion currently does more harm than good to each of these objectives because it is usually misleading. This is a systemic problem. Whilst improved regulation and education will address it to some degree, major reforms to payment systems for drug companies and doctors are also required. Until all these systemic reforms can be put in place, the best policy option is to ban the promotion of drugs to doctors and the public. Consequently, pending major reforms, it is appropriate for governments to restrict drug promotion as much as is politically achievable.

Keywords:  Health Care and Public Health; Legal Approach

Mesh:

Substances:

Year:  2005        PMID: 16317866     DOI: 10.1007/bf02448846

Source DB:  PubMed          Journal:  J Bioeth Inq        ISSN: 1176-7529            Impact factor:   1.352


  13 in total

1.  Timing of new black box warnings and withdrawals for prescription medications.

Authors:  Karen E Lasser; Paul D Allen; Steffie J Woolhandler; David U Himmelstein; Sidney M Wolfe; David H Bor
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

2.  Predictable surprises: the disasters you should have seen coming.

Authors:  Michael D Watkins; Max H Bazerman
Journal:  Harv Bus Rev       Date:  2003-03

3.  Healthy Skepticism's new AdWatch: understanding drug promotion.

Authors:  Peter R Mansfield
Journal:  Med J Aust       Date:  2003 Dec 1-15       Impact factor: 7.738

4.  Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion.

Authors:  Brad J Sagarin; Robert B Cialdini; William E Rice; Sherman B Serna
Journal:  J Pers Soc Psychol       Date:  2002-09

5.  Industrial interests versus public health: the gap is growing.

Authors: 
Journal:  Prescrire Int       Date:  2004-04

6.  The ethics of pharmaceutical industry relationships with medical students.

Authors:  Wendy A Rogers; Peter R Mansfield; Annette J Braunack-Mayer; Jon N Jureidini
Journal:  Med J Aust       Date:  2004-04-19       Impact factor: 7.738

7.  Psychological aspects of gifts from drug companies.

Authors:  Dana Katz; Peter Mansfield; Robert Goodman; Leonore Tiefer; Jon Merz
Journal:  JAMA       Date:  2003-11-12       Impact factor: 56.272

8.  Pharmaceutical advertisements in leading medical journals: experts' assessments.

Authors:  M S Wilkes; B H Doblin; M F Shapiro
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

Review 9.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

10.  Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.

Authors:  Paul E Langton; Graeme J Hankey; John W Eikelboom
Journal:  Med J Aust       Date:  2004-11-15       Impact factor: 7.738

View more
  6 in total

1.  Another way to tame the monster.

Authors:  Peter R Mansfield
Journal:  BMJ       Date:  2006-07-22

2.  Assessment of a Pharmaceutical Advertisement Analysis Module in a Drug Literature Evaluation Course.

Authors:  Mohamed Ezzat Khamis Amin; Youssef Fattouh
Journal:  Am J Pharm Educ       Date:  2017-08       Impact factor: 2.047

3.  What are the public health effects of direct-to-consumer drug advertising?

Authors:  Elizabeth A Almasi; Randall S Stafford; Richard L Kravitz; Peter R Mansfield
Journal:  PLoS Med       Date:  2006-03-28       Impact factor: 11.069

4.  Industry-sponsored research: a more comprehensive alternative.

Authors:  Peter Mansfield
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

5.  Educating health professionals about drug and device promotion: advocates' recommendations.

Authors:  Peter R Mansfield; Joel Lexchin; Leana S Wen; Luisella Grandori; Christopher P McCoy; Jerome R Hoffman; Joana Ramos; Jon N Jureidini
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

6.  Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study.

Authors:  Brett D Montgomery; Peter R Mansfield; Geoffrey K Spurling; Alison M Ward
Journal:  BMC Public Health       Date:  2008-05-20       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.